<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776642</url>
  </required_header>
  <id_info>
    <org_study_id>2014_054#A201436</org_study_id>
    <nct_id>NCT04776642</nct_id>
  </id_info>
  <brief_title>Biobank for &quot;Arrhythmia and Conduction Disorders: TowArd Pathophysiology Based Treatment&quot;</brief_title>
  <acronym>ADAPT</acronym>
  <official_title>&quot;Arrhythmia and Conduction Disorders: TowArd Pathophysiology Based Treatment&quot; ADAPT Biobank</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The 'ADAPT' Biobank is a collection of body material and data from patients with or at risk&#xD;
      of cardiac arrhythmias who underwent or will undergo (non-) invasive treatment for this&#xD;
      disease. Its main objective is to obtain a comprehensive collection of patient information&#xD;
      and material to facilitate research and gain better insight into the complex pathophysiology&#xD;
      of the different arrhythmias, the multifactorial process, the heterogeneity in clinical&#xD;
      presentation, and prognosis.&#xD;
&#xD;
      Bodily material is used for biochemical marker assessments, histological and molecular&#xD;
      analyses for research in cardiac arrhythmias.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiological process of many cardiac arrhythmias is complex because of its&#xD;
      multifactorial character. Despite extensive research that has already been performed in the&#xD;
      field of electrophysiology the exact pathophysiological process of the different arrhythmias&#xD;
      remains incompletely understood. The ability to identify subgroups of patients within a&#xD;
      population with the same type of arrhythmia that can benefit from a specific treatment&#xD;
      strategy might provide more individualized therapeutic opportunities, improve prognostication&#xD;
      or provide preventive opportunities in patient with cardiac arrhythmias. Biobanks can make a&#xD;
      valuable contribution to the development of diagnostic, preventive and therapeutic methods.&#xD;
      More insights into the correlations between genes, environmental factors and susceptibility&#xD;
      to illness may be of great value. The 'ADAPT' Biobank has been designed to establish a&#xD;
      systematic and qualitative collection of bodily materials for future research in the&#xD;
      cardiovascular field. The Biobank includes bodily material of patients with cardiac&#xD;
      arrhythmias undergoing (non-) invasive treatment or control patients undergoing&#xD;
      cardiothoracic surgery. Clinical data related to the cardiac arrhythmic disease is recorded.&#xD;
      The data and samples will be linked to the participants' medical records to allow&#xD;
      longitudinal follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2014</start_date>
  <completion_date type="Anticipated">January 2030</completion_date>
  <primary_completion_date type="Anticipated">January 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>(new onset) atrial fibrilation</measure>
    <time_frame>5 year follow up</time_frame>
    <description>obtain a comprehensive collection of patient information and material to facilitate research and gain better insight into the complex pathophysiology of the different arrhythmias</description>
  </primary_outcome>
  <primary_outcome>
    <measure>recurrence of cardia arrythmia</measure>
    <time_frame>5 year follow up</time_frame>
    <description>obtain a comprehensive collection of patient information and material to facilitate research and gain better insight into the complex pathophysiology of the different arrhythmias</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Arrythmia</condition>
  <condition>Conduction Disorder</condition>
  <condition>Pathophysiology</condition>
  <arm_group>
    <arm_group_label>MARK_AF</arm_group_label>
    <description>MARKers of ATrial Remodeling in Patietns with Atrial Fibrillation. Patients with paroxysmal and persistent atrial fibrillation undergoing thoracoscopic atrial fibrillation ablation surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>INDICO AF</arm_group_label>
    <description>Atrial Fibrillation in Patients With an Implantable Cardioverter Defibrillator and Coronary Artery Disease. Investigate the incidence of new-onset AF in patients with coronairy artery disease and an impaired LVEF, who will receive a single chamber ICD as primary prevention for sudden cardiac death.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PREDICT AF</arm_group_label>
    <description>PREDICT AF, Tissue, Blood and biomarkers to predict future Atrial Fibrillation. Patients without a history of atrial fibrillation undergoing cardiothoracic surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WEIGHTLOSS AF</arm_group_label>
    <description>The change of adipose tissue characteristics upon drastic weight loss: Implications for atrial fibrillation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD AF</arm_group_label>
    <description>(123I-mIBG And Defibrillation for Atrial Fibrillation) Enhanced sympathetic activity as a mechanism of Atrial Fibrillation. Patients will undergo 123I-mIBG scintigraphy within 7 days before and six week after an elective cardioversion is performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adapt Biobank - AF surgery</arm_group_label>
    <description>Patients with Atrial Fibrillation who only donate blood and tissue for the biobank. Patients undergo thorascopic surgery, LAA will be amputated, blood will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adapt Biobank - blood</arm_group_label>
    <description>Patients with cardiac arrhythmias who only donate blood for the ADAPT biobank.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biobank for Left atrial appendage tissue</intervention_name>
    <description>Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.</description>
    <arm_group_label>Adapt Biobank - AF surgery</arm_group_label>
    <arm_group_label>MARK_AF</arm_group_label>
    <arm_group_label>PREDICT AF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biobank for Blood</intervention_name>
    <description>Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.</description>
    <arm_group_label>Adapt Biobank - AF surgery</arm_group_label>
    <arm_group_label>Adapt Biobank - blood</arm_group_label>
    <arm_group_label>INDICO AF</arm_group_label>
    <arm_group_label>MAD AF</arm_group_label>
    <arm_group_label>MARK_AF</arm_group_label>
    <arm_group_label>PREDICT AF</arm_group_label>
    <arm_group_label>WEIGHTLOSS AF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biobank for One or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat, visceral fat.</intervention_name>
    <description>Bodily material is used for biochemical marker assessments, histological and molecular analyses for research in cardiac arrhythmias.</description>
    <arm_group_label>Adapt Biobank - AF surgery</arm_group_label>
    <arm_group_label>MARK_AF</arm_group_label>
    <arm_group_label>PREDICT AF</arm_group_label>
    <arm_group_label>WEIGHTLOSS AF</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  left atrial appendage tissue&#xD;
&#xD;
        -  blood&#xD;
&#xD;
        -  one or more of following fat patches: epicardial fat, subcutaneous fat, pericardial fat,&#xD;
           visceral fat.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with cardiac arrhythmia and are treated in the AMC Heart Center are&#xD;
        eligible to donate blood or other bodily material for the 'ADAPT' Biobank. Patient are&#xD;
        asked to participate in the 'ADAPT' Biobank during outpatient clinic visits or prior to&#xD;
        treatment for their arrhythmia.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Patients visiting the AMC outpatient clinic&#xD;
&#xD;
          -  Patients included in an ongoing clinical trial linked to this biobank. Studies are&#xD;
             listed under point &quot;Groups and interventions&quot; and include:&#xD;
&#xD;
               -  MARK AF&#xD;
&#xD;
               -  INDICO AF&#xD;
&#xD;
               -  PREDICT AF&#xD;
&#xD;
               -  WEIGHTLOSS AF&#xD;
&#xD;
               -  MAD AF&#xD;
&#xD;
          -  Patients included in future clinical trial linked to this biobank. Studies may be&#xD;
             linked to this biobank that investigates prevalent or incident cardiac arrhythmias.&#xD;
&#xD;
          -  Cardiac arrhtymias are defined as&#xD;
&#xD;
               -  Supraventricular tachycardia, among which the most common are:&#xD;
&#xD;
                    -  Atrial Fibrillation (AF)&#xD;
&#xD;
                    -  Atrial Tachycardia (AT)&#xD;
&#xD;
                    -  Atrial Flutter (AFL)&#xD;
&#xD;
                    -  Atrioventricular Nodal Reentrant Tachycardia (AVNRT)&#xD;
&#xD;
                    -  Atrioventricular Reentrant Tachycardia (AVRT)&#xD;
&#xD;
               -  Ventricular tachycardia, among which the most common are:&#xD;
&#xD;
                    -  Ventricular Tachycardia (VT)&#xD;
&#xD;
                    -  Ventricular Flutter (VFL)&#xD;
&#xD;
                    -  Ventricular Fibrillation (VF)&#xD;
&#xD;
               -  Bradycardia:&#xD;
&#xD;
                    -  Sinus Node Dysfunction&#xD;
&#xD;
                    -  AV Node Dysfunction&#xD;
&#xD;
                    -  Interventricular Conduction Disorder&#xD;
&#xD;
               -  Arrhythmogenic cardiomyopathies, among which the most common are:&#xD;
&#xD;
                    -  Dilated Cardiomyopathy&#xD;
&#xD;
                    -  Restrictive Cardiomyopathy&#xD;
&#xD;
                    -  Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)&#xD;
&#xD;
        Exclusion criteria (shared for all studies):&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Unable or unwilling to comply with study procedures&#xD;
&#xD;
          -  Pregnancy or of childbearing potential without adequate contraception&#xD;
&#xD;
          -  NYHA class IV heart failure symptoms or left ventricular ejection fraction &lt;35%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joris de Groot, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Amsterdam UMC - AMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elise Hulsman, Bc RN</last_name>
    <phone>31205665653</phone>
    <email>e.l.hulsman@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joris de Groot, MD, PhD</last_name>
    <phone>310205666555</phone>
    <email>j.r.degroot@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amsterdam University Medical Center location AMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>J.R. de Groot</investigator_full_name>
    <investigator_title>Prof.dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Cardiac Conduction System Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

